Humana Inc. has agreed to sell the stock of its subsidiary
Concentra Inc., one of the most important occupational fitness services
providers.
The consumer will be MJ Acquisition Corp., a joint task
between pick medical Holdings Corp., an operator of strong point hospitals and
outpatient rehabilitation clinics within the U.S., and Welsh, Carson, Anderson
& Stowe XII, L.P., a private equity fund, for about $1.0.5 billion in
coins.
Concentra is one of the nation’s largest vendors of
occupational fitness, pressing care and physical therapy offerings to employers
and consumers across the U.S. It stated it treats more than 14 percent of all
work-associated injuries national.
through its affiliated clinicians, the organisation promises
occupational medicinal drug, pressing care, primary care, physical remedy, and
health services to people and most people from more than 300 medical centers in
38 states. further to those scientific middle locations, Concentra operates more
than 245 worksite clinical facilities.
Humana received Concentra in December 2010. Humana said that as it has refined its method
over the past several years, it discovered that the number one care platform
become the better approach to increase the corporation’s incorporated care
delivery model than Concentra’s focus on occupational accidents.
“We greatly admire the point of interest on consumers and
first-rate of health care our Concentra buddies exhibit on a every day
foundation,” said Bruce D. Broussard, president and CEO of Humana. “although
Concentra’s operations did now not in the long run align with Humana’s approach
as well as we had at the beginning anticipated, we believe Humana and Concentra
have gained treasured insights into client conduct during the last several
years so that it will serve us both well shifting forward.”
Concentra reported $1.0 billion in revenues for the 12
months ended Dec. 31, 2014.
The Concentra transaction is anticipated to shut all through
the second one quarter of 2015.
Humana stated it expects to apply the internet proceeds from
the transaction to strengthen its strategic boom priorities, to fund additional
share repurchases below its present $2 billion authorization and for preferred
corporate functions.
No comments:
Post a Comment